US 11,717,558 B2
Nucleic acid molecules encoding activin receptor type IIA variants
Jasbir S. Seehra, Lexington, MA (US); and Jennifer Lachey, Lincoln, MA (US)
Assigned to Keros Therapeutics, Inc., Lexington, MA (US)
Filed by Keros Therapeutics, Inc., Lexington, MA (US)
Filed on May 24, 2021, as Appl. No. 17/327,914.
Application 17/327,914 is a division of application No. 16/348,987, granted, now 11,013,785, previously published as PCT/US2017/060960, filed on Nov. 9, 2017.
Claims priority of provisional application 62/531,943, filed on Jul. 13, 2017.
Claims priority of provisional application 62/420,476, filed on Nov. 10, 2016.
Prior Publication US 2021/0275637 A1, Sep. 9, 2021
Int. Cl. C07H 21/04 (2006.01); C12N 15/86 (2006.01); C07K 14/71 (2006.01); A61K 38/18 (2006.01); A61K 47/65 (2017.01); A61P 19/08 (2006.01); C07K 14/76 (2006.01); C12N 15/85 (2006.01); C12P 21/02 (2006.01); A61K 38/00 (2006.01); A61K 47/64 (2017.01)
CPC A61K 38/18 (2013.01) [A61K 47/65 (2017.08); A61P 19/08 (2018.01); C07K 14/71 (2013.01); C07K 14/76 (2013.01); C12N 15/85 (2013.01); C12P 21/02 (2013.01); A61K 38/00 (2013.01); A61K 47/64 (2017.08)] 12 Claims
 
1. A nucleic acid molecule encoding a polypeptide comprising an extracellular activin receptor type IIa (ActRIIa) variant and an Fc domain, the variant having a sequence of
(SEQ ID NO: 1)
GAILGRSETQECLX1X2NANWX3X4X5X6TNQTGVEX7CX8GX9X10X11X12
X13X14HCX15ATWX16NISGSIEIVX17X18GCX19X20X21DX22NCYDRTDCV
EX23X24X25X26PX27VYFCCCEGNMCNEKFSYFPEMEVTQPTS,
wherein X1 is F or Y; X2 is Y; X3 is E; X4 is L; X5 is D or E; X6 is R; X7 is P or R; X8 is E; X9 is E; X10 is K or Q; X11 is D; X12 is K; X13 is R; X14 is L; X15 is F or Y; X16 is K or R; X17 is K; X18 is K; X19 is W; X20 is L; X21 is D; X22 is I or F; X23 is T; X24 is K or E; X25 is E; X26 is N; and X27 is Q.